Randomized Open-Label Trial to Compare the Immunogenicity of Cell Culture-Based and Recombinant Unadjuvanted Quadrivalent Influenza Vaccines to Conventional Egg-Based Unadjuvanted Quadrivalent Influenza Vaccines Among Healthcare Personnel Aged 18-64 Years
Status: Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 19 Sep 2019
Price : $35 *
At a glance
- Drugs GSK 2321138A (Primary) ; Influenza vaccine (Optaflu) (Primary) ; Influenza virus RIV4 vaccine-(FluBlok Quadrivalent) (Primary) ; Influenza virus vaccine (Primary)
- Indications Influenza virus infections
- Focus Pharmacodynamics; Therapeutic Use
- 16 Sep 2019 Planned End Date changed from 30 Apr 2019 to 31 Jul 2020.
- 16 Sep 2019 Planned primary completion date changed from 30 Nov 2018 to 31 Jul 2020.
- 05 Nov 2018 New trial record